Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions
Abstract Background To compare the survival outcomes between breast-conserving surgery (BCS) and modified radical mastectomy (MRM), and to investigate the role of radiotherapy (RT) in patients with pT1–2N1M0 breast cancer. Methods A total of 4262 women with T1–2N1M0 breast cancer treated at two inst...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-11-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-020-07646-y |
id |
doaj-873376c5a5e7445e85af710b392b9f99 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Guang-Yi Sun Ge Wen Yu-Jing Zhang Yu Tang Hao Jing Jian-Yang Wang Jiang-Hu Zhang Yong Yang Xu-Ran Zhao Si-Ye Chen Jing Jin Yong-Wen Song Yue-Ping Liu Hui Fang Hua Ren Yuan Tang Shu-Nan Qi Ning Li Bo Chen Ning-Ning Lu Shu-Lian Wang Ye-Xiong Li |
spellingShingle |
Guang-Yi Sun Ge Wen Yu-Jing Zhang Yu Tang Hao Jing Jian-Yang Wang Jiang-Hu Zhang Yong Yang Xu-Ran Zhao Si-Ye Chen Jing Jin Yong-Wen Song Yue-Ping Liu Hui Fang Hua Ren Yuan Tang Shu-Nan Qi Ning Li Bo Chen Ning-Ning Lu Shu-Lian Wang Ye-Xiong Li Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions BMC Cancer Breast neoplasm Breast conserving surgery Mastectomy One to three positive nodes Radiotherapy |
author_facet |
Guang-Yi Sun Ge Wen Yu-Jing Zhang Yu Tang Hao Jing Jian-Yang Wang Jiang-Hu Zhang Yong Yang Xu-Ran Zhao Si-Ye Chen Jing Jin Yong-Wen Song Yue-Ping Liu Hui Fang Hua Ren Yuan Tang Shu-Nan Qi Ning Li Bo Chen Ning-Ning Lu Shu-Lian Wang Ye-Xiong Li |
author_sort |
Guang-Yi Sun |
title |
Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions |
title_short |
Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions |
title_full |
Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions |
title_fullStr |
Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions |
title_full_unstemmed |
Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions |
title_sort |
radiotherapy plays an important role in improving the survival outcome in patients with t1–2n1m0 breast cancer – a joint analysis of 4262 real world cases from two institutions |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2020-11-01 |
description |
Abstract Background To compare the survival outcomes between breast-conserving surgery (BCS) and modified radical mastectomy (MRM), and to investigate the role of radiotherapy (RT) in patients with pT1–2N1M0 breast cancer. Methods A total of 4262 women with T1–2N1M0 breast cancer treated at two institutions were retrospectively reviewed. A total of 3858 patients underwent MRM, and 832 (21.6%) of them received postoperative RT (MRM + RT). A total of 404 patients received BCS plus postoperative RT (BCS + RT). All patients received axillary lymph node dissection, while 3.8% of them had upfront sentinel node biopsy. The association of survival outcomes with different surgical modalities (BCS vs. MRM) and the role of RT were evaluated using multivariable proportional hazards regression and confirmed by the propensity score-matching (PSM) method. Results At a median follow-up of 71 months (range of 6–230 months), the 5-year overall survival (OS) rates of the BCS and MRM groups were 96.5 and 92.7%, respectively (P = .001), and the corresponding 5-year disease-free-survival (DFS) and locoregional recurrence (LRR) rates were 92.9 and 84.0%, and 2.0 and 7.0% (P = .001), respectively (P < .001). Multivariate analysis revealed that RT was an independent prognostic factor for improved OS (P = .001) and DFS (P = .009), and decreased LRR (P < .001). However, surgery procedure was not independently associated with either OS (P = .495), DFS (P = .204), or LRR (P = .996), which was confirmed by PSM analysis. Conclusion Postoperative radiotherapy rather than the surgery procedures was associated with superior survival outcomes in patients with T1–2N1M0 breast cancer. |
topic |
Breast neoplasm Breast conserving surgery Mastectomy One to three positive nodes Radiotherapy |
url |
http://link.springer.com/article/10.1186/s12885-020-07646-y |
work_keys_str_mv |
AT guangyisun radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT gewen radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT yujingzhang radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT yutang radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT haojing radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT jianyangwang radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT jianghuzhang radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT yongyang radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT xuranzhao radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT siyechen radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT jingjin radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT yongwensong radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT yuepingliu radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT huifang radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT huaren radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT yuantang radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT shunanqi radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT ningli radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT bochen radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT ningninglu radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT shulianwang radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions AT yexiongli radiotherapyplaysanimportantroleinimprovingthesurvivaloutcomeinpatientswitht12n1m0breastcancerajointanalysisof4262realworldcasesfromtwoinstitutions |
_version_ |
1724414579762528256 |
spelling |
doaj-873376c5a5e7445e85af710b392b9f992020-11-26T12:52:49ZengBMCBMC Cancer1471-24072020-11-0120111110.1186/s12885-020-07646-yRadiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutionsGuang-Yi Sun0Ge Wen1Yu-Jing Zhang2Yu Tang3Hao Jing4Jian-Yang Wang5Jiang-Hu Zhang6Yong Yang7Xu-Ran Zhao8Si-Ye Chen9Jing Jin10Yong-Wen Song11Yue-Ping Liu12Hui Fang13Hua Ren14Yuan Tang15Shu-Nan Qi16Ning Li17Bo Chen18Ning-Ning Lu19Shu-Lian Wang20Ye-Xiong Li21State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer MedicineDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer MedicineState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Background To compare the survival outcomes between breast-conserving surgery (BCS) and modified radical mastectomy (MRM), and to investigate the role of radiotherapy (RT) in patients with pT1–2N1M0 breast cancer. Methods A total of 4262 women with T1–2N1M0 breast cancer treated at two institutions were retrospectively reviewed. A total of 3858 patients underwent MRM, and 832 (21.6%) of them received postoperative RT (MRM + RT). A total of 404 patients received BCS plus postoperative RT (BCS + RT). All patients received axillary lymph node dissection, while 3.8% of them had upfront sentinel node biopsy. The association of survival outcomes with different surgical modalities (BCS vs. MRM) and the role of RT were evaluated using multivariable proportional hazards regression and confirmed by the propensity score-matching (PSM) method. Results At a median follow-up of 71 months (range of 6–230 months), the 5-year overall survival (OS) rates of the BCS and MRM groups were 96.5 and 92.7%, respectively (P = .001), and the corresponding 5-year disease-free-survival (DFS) and locoregional recurrence (LRR) rates were 92.9 and 84.0%, and 2.0 and 7.0% (P = .001), respectively (P < .001). Multivariate analysis revealed that RT was an independent prognostic factor for improved OS (P = .001) and DFS (P = .009), and decreased LRR (P < .001). However, surgery procedure was not independently associated with either OS (P = .495), DFS (P = .204), or LRR (P = .996), which was confirmed by PSM analysis. Conclusion Postoperative radiotherapy rather than the surgery procedures was associated with superior survival outcomes in patients with T1–2N1M0 breast cancer.http://link.springer.com/article/10.1186/s12885-020-07646-yBreast neoplasmBreast conserving surgeryMastectomyOne to three positive nodesRadiotherapy |